EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:50123 - (+)-rosiglitazone
| Formula | C18H19N3O3S |
| Net Charge | 0 |
| Average Mass | 357.435 |
| Monoisotopic Mass | 357.11471 |
| SMILES | CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |
| InChI | InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)/t15-/m1/s1 |
| InChIKey | YASAKCUCGLMORW-OAHLLOKOSA-N |
| Roles Classification |
|---|
| Chemical Roles: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | anti-HIV agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. antimalarial A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. insulin-sensitizing drug An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). ferroptosis inhibitor Any substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms. EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor An EC 6.2.1.* (acid-thiol ligase) inhibitor that interferes with the action of a long-chain-fatty-acid—CoA ligase (EC 6.2.1.3). |
| Applications: | antirheumatic drug A drug used to treat rheumatoid arthritis. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. antiemetic A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. anti-inflammatory agent Any compound that has anti-inflammatory effects. antiatherosclerotic agent A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. antimalarial A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. insulin-sensitizing drug An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). anti-asthmatic agent Any compound that has anti-asthmatic effects. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. vasodilator agent A drug used to cause dilation of the blood vessels. anti-anaemic agent A compound which increases either the number of red cells or the amount of haemoglobin in the blood. hypoglycemic agent A drug which lowers the blood glucose level. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| (+)-rosiglitazone (CHEBI:50123) is a rosiglitazone (CHEBI:50122) |
| (+)-rosiglitazone (CHEBI:50123) is enantiomer of (−)-rosiglitazone (CHEBI:50125) |
| Incoming Relation(s) |
| (−)-rosiglitazone (CHEBI:50125) is enantiomer of (+)-rosiglitazone (CHEBI:50123) |
| IUPAC Name |
|---|
| (5R)-5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione |
| Manual Xrefs | Databases |
|---|---|
| DB00412 | DrugBank |
| Registry Numbers | Sources |
|---|---|
| Beilstein:7082203 | Beilstein |